Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.

ABSTRACT: Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations. This new paradigm has substantially highlighted the treatment of advanced NSCLC, shifting it from standard chemotherapy according to specific histologic subtypes to targeted therapy according to specific oncogenic drivers. The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring activating EGFR mutations has been a representative model of precise medicine in the treatment of NSCLC. As th

SUBMITTER: Zhou F 

PROVIDER: S-EPMC4593374 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature